metabolic processes are not efficiently sequestered in the vacuole. If this were the case, fluconazole's 49 antifungal activity might be potentiated by other drugs which also acidify the cytosol. 50 51 Proton pump inhibitors (PPIs), sold over the counter like omeprazole, or by prescription, like 52 rabeprazole, are taken by millions of patients each year (6). In 2009, a PPI was prescribed at 79.4 53 million physician visits in the United States (5). Omeprazole has an antifungal effect and is known to 54 inhibit the fungal plasma membrane proton ATPase Pma1 (10). 55
56
We wanted to test the idea that blocking outflow of protons from the fungal cytosol into the 57 extracellular space with omeprazole (10), while perturbing proton pumping from the cytosol into the 58 vacuole with fluconazole (19), may result in toxic acidification of the cytosol and antifungal synergy. 59
We first confirmed the inhibitory effect of omeprazole on C. albicans (Fig. 1A) . 60
61
To test the effect of the drug combination, overnight-grown cells were diluted to an OD600 of 0.1 in 62 microtiter plates containing RPMI1640 (Lifetech) 2% glucose, buffered to pH 7.0 with 165 mM 63 MOPS, pH5 with 50 mM MES or pH 3.0 with 50 mM sodium citrate, and two-fold serial drug dilutions, 64 or drug vehicle, DMSO. The OD600 was measured after 24 hours' incubation at 35°C. Experiments 65 involving omeprazole, which needs to be activated to the H + ,K + -ATPase-binding sulfenamide by low 66 pH (10) (and whose active sulfenamide form is unstable at pH>4), were performed at pH 3, after 67
confirming fluconazole activity at pH 3 (Fig. S1) . Rabeprazole, whose molecular interaction with the 68 gastric H + ,K + -ATPase differs slightly from that of omeprazole, and which is activated in higher pH but 69 is less stable at neutral pH than omeprazole (16), was tested at pH7, after pre-activation of the 70 compound for one hour in the presence of 0.1 M HCI prior to addition to culture media. Cells were 71 inoculated at OD600 0.1 into RPMI, which was buffered to pH3 or 7 as above, and contained two- To directly examine the effect of these drugs on cytosolic pH, we adapted a ratiometric pHluorin 83 protein (9) to C. albicans codon usage. The synthesized gene (GenScript, Piscataway, NJ) was cloned 84 into plasmid pJK1027 (13) behind the strong ACT1 promoter and integrated at the ACT1 locus in 85 strain JKC915 (15) to create JKC1559, the strain used in this study. Cytosolic pH of cells exposed to 86 fluconazole, omeprazole, and their combination was determined as described in (3), by measuring 87 fluorescence emission at 508nm with excitation at 405nm and 485nm, and calculating pH using a 88 calibration curve ( Fig. 2A and B) . To generate the calibration curves, pHluorin-expressing, 89 permeabilized cells were equilibrated in 6 buffers of increasing pH (pH5-8). 20μl cell suspension 90 was added to 2ml calibration buffer and incubated at 30°C for 60 min before obtaining 91 measurements of emission intensity at 508nm during excitation at 405 and at 485 nm. Three 92 biological replicates, each comprising three technical replicates, were obtained for each condition. 93
All measurements were graphed and statistically analyzed using Prism software (GraphPad Software, 94
San Diego California), applying Student's two-tailed t-test to calculate p values. 95
96
The cytosolic pH of omeprazole-treated cells dropped, consistent with the concept that omeprazole 97 inhibits Pma1 (Fig. 2B ). Contrary to our prediction, the cytosol of fluconazole-treated cells was not 98 acidified (Fig. 2B) . Adding fluconazole to omeprazole normalized the cytosolic pH (Fig. 2B) , 99 antagonizing the effect of omeprazole. Low concentrations of the beta-1,3 D-glucan synthase 100 inhibitor micafungin, as a control for general fungal cell damage, alkalinized cytosolic pH (Fig. 2B) , 101 confirming the specificity of each drug's effect. 102
103
To test whether omeprazole antagonized alkalinization of the fungal vacuole caused by fluconazole 104 (19), we measured vacuolar pH of cells exposed to these drugs (Fig. 2C,D) , using BCECF-AM 105 (Lifetech), a pH-sensitive fluorophore that accumulates in the yeast vacuole, as in (3). To generate 106 calibration curves (Fig. 2C) , cells pre-incubated with BCECF were permeabilized and equilibrated in 107 6 buffers of increasing pH. 20μl cell suspension was added to 2ml calibration buffer (pH5-8) and 108 incubated at 30°C for 60 min, as described in (3). Replicates and calculations were performed as for 109 cytosolic pH. Fluconazole-exposed cells lost vacuolar acidification as expected (19) (Fig. 2D) . 110
Contrary to our expectation, the vacuolar pH of omeprazole-treated cells, and cells treated with both 111 drugs, also showed a trend toward alkalinization (Fig. 2D ). Exposure to a low concentration of 112 micafungin strongly acidified the vacuole, confirming the specific effect of fluconazole and 113 omeprazole on vacuolar pH. We did not identify the mechanism by which omeprazole antagonizes 114 the fungistatic effect of fluconazole. 115
116
We examined omeprazole concentrations in the range of 10μM, as they occur in human plasma 117 during omeprazole treatment with standard doses e.g. for gastric reflux disease (7), for the interaction 118 studies with fluconazole. At these concentrations, omeprazole alone had no effect on C. albicans 119 growth (Fig. 1A) , but did antagonize the fungistatic effect of fluconazole (Fig. 1B-D) . Only at 40-fold 120 higher concentrations did omeprazole alone exert an inhibitory effect on C. albicans (Fig. 1A) . In 121 clinical practice, such high concentrations are unlikely to occur, so that we do not expect omeprazole 122 alone to have utility as an antifungal. We tested rabeprazole, which is activated at slightly higher pHthan omeprazole, at pH7. We found that in these conditions, its concentrations antagonizing 124 fluconazole were ~32 fold higher than standard plasma levels during rabeprazole therapy (14) In conclusion, critical assessment of all drugs used in treating ill patients is necessary not only 139 because of potential drug interactions in the patient. Apparently in patients with invasive fungal 140 disease, drugs active on human targets may also elicit unexpected and undesirable effects on the 141 infecting fungus. Given the very widespread usage of PPIs (6), it may not be possible to confirm this 142 effect in a clinical study, since a sufficiently large patient group not prescribed a PPI may be difficult 143 to recruit. Nevertheless, our results underscore the importance of critically assessing patients' needs 144 for long-term medications, and of avoiding unnecessary medication use (6). In addition, they 145 underscore the importance of testing not only human pharmacokinetics (11), but also 146 pharmacodynamics toward the fungus, of drug combinations for invasive fungal infections. 147 
